Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM ESTBMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More
Streetinsider.com's Hot Lunchtime Reads 11/23: (JUNO) (AMZN) (AXON) (LLY)
November 23, 2016 12:30 PM ESTThe following is a list of notable articles to help get you through the lunch hour:Amazon.com (AMZN) Said Planning New Video Chat Service Following Recent Acquisition ->... More
Eli Lilly & Co. (LLY) 30-day call option implied volatility is at 66, compared to a one month ago level of 24.
November 23, 2016 11:47 AM ESTEli Lilly & Co. (NYSE: LLY) 30-day call option implied volatility is at 66, compared to a one month ago level of 24.
... MoreLilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody's
November 23, 2016 11:41 AM ESTMoody's Investor Service commented that Eli Lilly and Company's (NYSE: LLY) announcement that its experimental Alzheimer's disease drug solanezumab did not meet the endpoint in a Phase III trial is credit negative. There is no effect on Lilly's A2 rating or stable rating outlook.
... MoreOptions with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MU
November 23, 2016 9:51 AM ESTOptions with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MU
... MoreNeurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease
November 23, 2016 9:50 AM ESTNeurotrope, Inc. (OTC: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, issued a statement on Eli Lilly's (NYSE: LLY) experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease.
Dr. Daniel Alkon,... More
Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
November 23, 2016 9:24 AM ESTToday's Pre-Open Stock Movers
Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.
Euroseas Ltd. (Nasdaq:... More
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM ESTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More
Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola Failure
November 23, 2016 7:50 AM ESTAxovant Sciences (NYSE: AXON) is down 17% in pre-open trade after Eli Lilly & Co. (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreEli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM ESTLeerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes the future of the company's AD portfolio uncertain.
Fernandez commeted, "This morning LLY announced that its EXPEDITION 3 trial of solanezumab (sola) did NOT... More
Dow, S&P 500 set record high closes ahead of holiday
November 23, 2016 7:33 AM ESTBy Caroline Valetkevitch
NEW YORK (Reuters) - The Dow and the S&P 500 eked out record high closes on Wednesday ahead of the Thanksgiving holiday, helped by gains in industrial stocks, though losses in technology shares limited the advance and weighed on the Nasdaq.
Caterpillar (NYSE: CAT) rose 2.7 percent and hit the highest in about two years, while Deere (NYSE: DE) jumped 11 percent to a record high close after the farm equipment maker reported a much smaller-than-expected decline in profit.
Industrial... More
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM ESTEli Lilly & Co. (NYSE: LLY) CEO John Lechleite says there's no concern about the company's dividend, according to CNBC.
David A. Ricks. Senior Vice President and President, Lilly Bio-Medicines, also added that investors want the company to continue exploring solutions for Alzheimer's disease.
... MoreEli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM ESTEli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreBiogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM ESTBiogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreEli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
November 23, 2016 6:51 AM ESTEli Lilly & Co. (NYSE: LLY) November weekly call option implied volatility is at 78, December is at 70, January is at 49; compared to its 52-week range of 14 to 64 into the solanezumab data for Alzheimer's.
... MoreEli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
November 23, 2016 6:45 AM ESTEli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).
While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small.... More
